Overview

Pharmacokinetic and Pharmacodynamic Evaluation of Formulations of Δ9-THC

Status:
Not yet recruiting
Trial end date:
2024-08-17
Target enrollment:
Participant gender:
Summary
Study based on the pharmacokinetic, pharmacodynamic, safety and stability evaluation of 3 standardized formulations of THC, to be used in healthy volunteers and post-chemotherapy patients as an adjuvant in the symptomatic treatment of the latter in discomfort associated with cancer treatment, with the aim of possible new therapeutic entities.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
LaSanta S A S
Treatments:
Dronabinol